SCHEMBL30294377

SCHEMBL30294377

Cc1cc(F)ccc1Nc1cc(F)c(F)cc1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.48
CLCN2 P51788 1/20 0.48
P2RY4 P51582 1/20 0.47
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45
DHODH Q02127 5/20 0.44
FTO Q9C0B1 2/20 0.44
MKNK2 Q9HBH9 1/20 0.44
MAPK13 O15264 1/20 0.44
MAPK12 P53778 1/20 0.44
MAPK11 Q15759 1/20 0.44
MAPK14 Q16539 1/20 0.44
FABP3 P05413 1/20 0.44
FABP4 P15090 1/20 0.44
CTSV O60911 2/20 0.43
CTSL P07711 2/20 0.43
MPO P05164 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22853121 1.00 IDO1 (0.48) IDO1CLCN2P2RY4KDM4ELMNA
SCHEMBL30294440 0.93 IDO1 (0.50) IDO1CLCN2P2RY4KDM4ELMNA
SCHEMBL22853346 0.93 IDO1 (0.50) IDO1CLCN2P2RY4KDM4ELMNA
SCHEMBL22853383 0.89 P2RY4 (0.56) IDO1CLCN2P2RY4LMNADHODH
SCHEMBL30294653 0.89 P2RY4 (0.56) IDO1CLCN2P2RY4LMNADHODH
SCHEMBL22853082 0.89 CLCN2 (0.53) IDO1CLCN2P2RY4DHODHFTO
SCHEMBL30294669 0.89 CLCN2 (0.53) IDO1CLCN2P2RY4DHODHFTO
SCHEMBL22852820 0.89 IDO1 (0.44) IDO1CLCN2P2RY4LMNADHODH
SCHEMBL30294688 0.89 IDO1 (0.44) IDO1CLCN2P2RY4LMNADHODH
SCHEMBL30294647 0.89 CLCN2 (0.53) IDO1CLCN2P2RY4DHODHFTO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230103791-A1 2,3-DIHYDROQUINAZOLIN COMPOUNDS AS NAV1.8 INHIBITORS SCN8A, SCN1A, SCN1B IDO1 3449/4885CLCN2 192/4885P2RY4 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.